Chronic Heart Failure Analysis and Registry in the Tohoku District 2 (CHART-2 Study)
NCT ID: NCT00418041
Last Updated: 2015-05-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
10000 participants
OBSERVATIONAL
2006-10-31
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Characteristics of patients with chronic heart failure and prognostic risks of these patients.
* Characteristics of patients with high risk for heart failure and critical factors which predict the development of symptomatic heart failure in these patients.
* The incidence and prognostic impact of metabolic syndrome in patients with chronic heart failure.
* The association between metabolic syndrome and the development of symptomatic heart failure.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Mulltimodal Dynamic Risk Assessment Systems of Heart Failure in Patients With Myocardial Infarction.
NCT05760157
Incidence Rate of Heart Failure After Acute Myocardial Infarction With Optimal Treatment
NCT03297164
Fast-Track Cardiovascular Assessment for Suspicion of Cardiovascular Events on Immunecheckpoint Inhibitors
NCT05799898
Myocardial Ischemia in Non-obstructive Coronary Artery Disease
NCT01853527
SECURE Trial: Stress Echocardiography With Carotid Ultrasound vs Routine CT Coronary Angiography in Chronic Coronary Syndrome for Endpoints
NCT06185530
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The purposes of the study are as follows:
1. to elucidate characteristics of patients with overt HF and the associated prognostic risks
2. to elucidate characteristics of patients at risk for HF and the factors associated with CVD progression
3. to elucidate factors associated with the development of AHFS
4. to elucidate prevalence and prognostic impact of metabolic syndrome (MetS) in patients with overt HF
5. to elucidate the association between MetS and the development of AHFS
6. to elucidate the prevalence and prognostic impact of malignancy in patients with CVD
7. to elucidate the prevalence of patients needing home nursing care and the characteristics of bedridden patients with CVD.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Structural heart disease with prior or current symptoms of heart failure.
* Refractory heart failure requiring specialized interventions.
* Patients with prior cardiovascular surgery or percutaneous coronary intervention and those who need such interventions.
Exclusion Criteria
* Patients who refused to participate.
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hiroaki Shimokawa, MD, PhD
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hiroaki Shimokawa, MD, PhD
Department of Cardiovascular Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hiroaki Shimokawa, MD, PhD
Role: STUDY_CHAIR
Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine
Sendai, , Japan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ito T, Nochioka K, Noda T, Shiroto T, Yamanaka S, Yamamoto N, Sato H, Chiba T, Nakano M, Inoue T, Susukita K, Takahama H, Takahashi J, Miyata S, Shimokawa H, Yasuda S. New-onset anemia and its association with ventricular arrhythmias and sudden cardiac death in patients with heart failure with preserved ejection fraction. Int J Cardiol Heart Vasc. 2025 Sep 25;61:101812. doi: 10.1016/j.ijcha.2025.101812. eCollection 2025 Dec.
Ito T, Noda T, Nochioka K, Shiroto T, Yamamoto N, Sato H, Hayashi H, Chiba T, Nakano M, Takahama H, Takahashi J, Miyata S, Shimokawa H, Yasuda S. Association of a mild or an important decline in left ventricular ejection fraction with ventricular tachyarrhythmias, sudden cardiac death, and all-cause death in heart failure with preserved ejection fraction: a report from the CHART-2 Study. Europace. 2025 Sep 1;27(9):euaf184. doi: 10.1093/europace/euaf184.
Ito T, Noda T, Nochioka K, Shiroto T, Yamamoto N, Sato H, Chiba T, Hasebe Y, Nakano M, Takahama H, Takahashi J, Miyata S, Shimokawa H, Yasuda S. Clinical impact of atrial fibrillation progression in patients with heart failure with preserved ejection fraction: A report from the CHART-2 Study. Europace. 2024 Aug 30;26(9):euae218. doi: 10.1093/europace/euae218.
Aoyanagi H, Nochioka K, Sakata Y, Miura M, Shiroto T, Abe R, Kasahara S, Sato M, Fujihashi T, Yamanaka S, Hayashi H, Sugimura K, Takahashi J, Miyata S, Shimokawa H; CHART-2 Investigators. Temporal changes in left ventricular ejection fraction and their prognostic impacts in patients with Stage B heart failure. Int J Cardiol. 2020 May 1;306:123-132. doi: 10.1016/j.ijcard.2020.02.040. Epub 2020 Feb 15.
Takada T, Sakata Y, Nochioka K, Miura M, Abe R, Kasahara S, Sato M, Aoyanagi H, Fujihashi T, Yamanaka S, Suzuki K, Shiroto T, Sugimura K, Takahashi J, Miyata S, Shimokawa H; CHART-2 Investigators. Risk of de-novo heart failure and competing risk in asymptomatic patients with structural heart diseases. Int J Cardiol. 2020 May 15;307:87-93. doi: 10.1016/j.ijcard.2020.02.015. Epub 2020 Feb 6.
Suzuki K, Oikawa T, Nochioka K, Miura M, Kasahara S, Sato M, Aoyanagi H, Shiroto T, Takahashi J, Miyata S, Sakata Y, Shimokawa H. Elevated Serum Non-HDL (High-Density Lipoprotein) Cholesterol and Triglyceride Levels as Residual Risks for Myocardial Infarction Recurrence Under Statin Treatment. Arterioscler Thromb Vasc Biol. 2019 May;39(5):934-944. doi: 10.1161/ATVBAHA.119.312336.
Oikawa T, Sakata Y, Nochioka K, Miura M, Tsuji K, Onose T, Abe R, Kasahara S, Sato M, Shiroto T, Takahashi J, Miyata S, Shimokawa H; CHART-2 invesigators. Prognostic Impact of Statin Intensity in Heart Failure Patients With Ischemic Heart Disease: A Report From the CHART-2 (Chronic Heart Failure Registry and Analysis in the Tohoku District 2) Study. J Am Heart Assoc. 2018 Mar 14;7(6):e007524. doi: 10.1161/JAHA.117.007524.
Ushigome R, Sakata Y, Nochioka K, Miyata S, Miura M, Tadaki S, Yamauchi T, Sato K, Onose T, Tsuji K, Abe R, Oikawa T, Kasahara S, Takahashi J, Shimokawa H; CHART-2 Investigators. Temporal trends in clinical characteristics, management and prognosis of patients with symptomatic heart failure in Japan -- report from the CHART Studies. Circ J. 2015;79(11):2396-407. doi: 10.1253/circj.CJ-15-0514. Epub 2015 Sep 10.
Miura M, Sakata Y, Miyata S, Nochioka K, Takada T, Tadaki S, Takahashi J, Shiba N, Shimokawa H; CHART-2 Investigators. Usefulness of combined risk stratification with heart rate and systolic blood pressure in the management of chronic heart failure. A report from the CHART-2 study. Circ J. 2013;77(12):2954-62. doi: 10.1253/circj.cj-13-0725. Epub 2013 Oct 1.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2006-115
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.